Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | RPRX Royalty Pharma plc | AAPG Ascentage Pharma Group International - American Depository |
|---|---|---|
| Price | $57.65 -1.4% | $15.58 -1.8% |
| StockIQ Score | 46D+ Moderate Risk: Medium | 37F Weak Risk: Medium |
| Technical | 35F | 16F |
| Fundamental | 60C+ | 35F |
| Growth | 40D | 50C- |
| Fair Value | 50C- | 38F |
| News | 50C- | 50C- |
| Quality | 42D | 50C- |
| Risk | 56C | 48D+ |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
Royalty Pharma (RPRX) outperforms Ascentage Pharma (AAPG) in most categories. Its investor score (60 vs. 37) and technical score (68 vs. 18) are significantly stronger, reflecting better market sentiment and short-term performance. While AAPG has a slightly higher growth score (50 vs. 40), RPRX’s overall "MODERATE" rating is more favorable than AAPG’s "WEAK." Valuation and fundamentals are closer, but RPRX leads in stability.
